Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
Filter the results
Michel Pettigrew, President of the Executive Board and Chief Operating Officer at Ferring Pharmaceuticals, explains how his company’s decentralised model and focus on entrepreneurialism is helping it to deliver personalised medicine.
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Non-inferiority was demonstrated in a Phase 3 trial for the co-primary endpoints of ongoing pregnancy rate and ongoing implantation rate for Rekovelle...
4 July 2016 | By Victoria White, Digital Content Producer
ESTHER-1 assessed an individualised dosing regimen of follitropin delta compared to follitropin alfa in women undergoing their first cycle of IVF...
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
17 August 2015 | By Victoria White
Ferring Pharmaceuticals has started patient enrollment in a Phase 2b/3 clinical trial of selepressin for the treatment of septic shock...